About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiology
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
S
Serial CDK4/6 Inhibitor Therapy for HR+-HER2- MBC: Evolving Insights, Key Questions, and Ongoing Studies
By
Seth Wander
5 Videos
427 views
August 13, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
02:58
Lilly Medical Affairs
A Heterogenous Disease with Varied Clinical Outcomes: HR+/HER2- MBC
Feat.
J. O’Shaughnessy
Featured Video
03:57
Lilly Medical Affairs
Resistance Mechanisms to ET, Including ESR1 Mutations in HR+, HER2- …
Feat.
K. Jhaveri
Related Content
AUTOPLAY
ON
Fred Hutchinson Cancer Center
Breast Oncology, Best of 2024
Wed, Oct 30, 2024
25:08
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights - Monday Morning Practice
Feat.
S. Tolaney,
H. Rugo
12:14
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Breast Cancer Highlights: Top 5 Abstracts - DESTINY-Breas…
Feat.
P. Tarantino
11:31
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Top 5 Abstracts Summary: "SONIA, NATALEE, PHERGain, …
Feat.
P. Tarantino
07:23
Total Health
Advanced Stage HR+ BC: Fine-Tuning Sequential Endocrine and Targeted…
Feat.
R. O'Regan
12:35
Insights from 2023 SABCS
SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…
Feat.
S. Tolaney,
H. Rugo
10:53
Kirollos Hanna
Integrating Oral Therapy for Patients With HR+/HER2- Early Stage BC
03:40
Integrity CE
SABCS 2023 Insights: "CAPItello-291 Trial - Capivasertib & …
Feat.
A. Bardia
09:55
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The ABCs of ADCs - What Does the Future H…
Feat.
E. Hamilton
14:16
Dana-Farber Cancer Institute
Year in Review: Breast Cancer
Feat.
P. Tarantino
17:39
Yale School of Medicine
2023 Menopause Update
Feat.
M. Minkin
17:12
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Breast Canc…
Feat.
A. Faso,
B. Patel,
K. Chen
05:43
Total Health
Neoadjuvant Chemo for HR+ BC: Year in Review
Feat.
C. Ma
17:20
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Summary: "Top 5 Breast Cancer Studies Including KEYNO…
Feat.
P. Tarantino
36:18
Insights from ESMO Breast 2024 Annual Meeting
Metastatic Breast Cancer Comprehensive Review: ESMO Breast 2024 Awar…
Feat.
H. Rugo
27:01
Scripps Health
CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC
Feat.
S. Sammons
57:44
Vogl, NY
Vogl,NY on How to Ask Good Questions at Medical Meetings
Feat.
S. Vogl
33:44
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Expert Recap: "Metastatic Breast Cancer Deep Dive &a…
Feat.
S. Tolaney,
H. Rugo
22:34
Dana-Farber Cancer Institute
What's New in Breast Cancer?
Feat.
S. Tolaney
10:34
Sara Tolaney
ASCO® 2024 Noteworthy Abstracts in Breast Cancer
Feat.
H. Rugo
16:19
Wassim Mchayleh
Optimizing Adjuvant Treatment in High-Risk HR+/HER2- eBC: Patient Se…
